RealFeedApp German biotech presents phase 1 data
Phase 1 data showed tumor shrinkage in all 16 patients with uveal melanoma after receiving experimental cell therapy. Results suggest the therapy could unlock immunotherapy power for other stubborn cancers.
- Field
- cancer research
- What they did
- Researchers from a German biotech company conducted Phase 1 trials on 16 patients with rare eye cancer (uveal melanoma), showing that tumors shrank in all of them after receiving experimental cell therapy.
- Why it matters
- The data suggest this method could be effective for other common cancers, such as pancreatic and ovarian tumors, which have previously resisted such treatments.
#cell therapy#uveal melanoma#immunotherapy#clinical trial
